Cargando…
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
Chronic Myeloid Leukemia (CML) is a disease arising in stem cells expressing the BCR-ABL oncogenic tyrosine kinase that transforms one Hematopoietic stem/progenitor Cell into a Leukemic Stem Cell (LSC) at the origin of differentiated and proliferating leukemic cells in the bone marrow (BM). CML-LSCs...
Autores principales: | Muselli, Fabien, Peyron, Jean-François, Mary, Didier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888542/ https://www.ncbi.nlm.nih.gov/pubmed/31717629 http://dx.doi.org/10.3390/ijms20225616 |
Ejemplares similares
-
Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia
por: Muselli, Fabien, et al.
Publicado: (2023) -
Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
por: Laverdière, Isabelle, et al.
Publicado: (2018) -
Leukemic stem cells and therapy resistance in acute myeloid leukemia
por: Stelmach, Patrick, et al.
Publicado: (2023) -
Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
por: Parting, Oliver, et al.
Publicado: (2020) -
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
por: Soverini, Simona, et al.
Publicado: (2021)